Table 1.
Average values (median ± median absolute deviation) for all markersa
| Group | 14 d after second dose |
6 mo after second dose |
||||
|---|---|---|---|---|---|---|
| Anti-S1 IgA (OD ratio) | Anti-S1 IgG (BAU/mL) | Neutral. antibodies (%) | Anti-S1 IgA (OD ratio) | Anti-S1 IgG (BAU/mL) | Neutral. antibodies (%) | |
| Whole cohort | 12 ± 0 | 3744 ± 2571.4 | 100 ± 0 | 1.98 ± 1.75 | 253 ± 144 | 82 ± 19.3 |
| Women | 12 ± 0 | 3830.4 ± 2585.7 | 100 ± 0 | 1.85 ± 1.61 | 246 ± 138 | 81 ± 19.3 |
| Men | 12 ± 0 | 3564.8 ± 2495.5 | 100 ± 0 | 2.35 ± 1.79 | 280 ± 160 | 84 ± 16.3 |
| Previously infected | 12 ± 0 | 3323.2 ± 517.1 | 100 ± 0 | 7.46 ± 3.77 | 298 ± 26.6 | 98 ± 3 |
| BNT162b2 | 12 ± 0 | 3654.4 ± 2571.4 | 100 ± 0 | 1.89 ± 1.53 | 243 ± 143 | 81 ± 19.3 |
| mRNA-1273 | 12 ± 0 | 4926.4 ± 3598.6 | 100 ± 0 | 5.38 ± 3.91 | 429 ± 289 | 90.5 ± 12.6 |
a
Results measured at 6 months after the second vaccination for the whole cohort and the following subgroups: women, men, participants previously infected with SARS-CoV-2, participants who received BNT162b2, and participants who received mRNA-1273. Shown are data for the time points 2 weeks after the second vaccination (data already published elsewhere) and 6 months after the second vaccination (data newly accumulated).